Canaccord Genuity Maintains Buy on Verve Therapeutics, Raises Price Target to $39

Benzinga · 04/15 12:38
Canaccord Genuity analyst Whitney Ijem maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and raises the price target from $32 to $39.